179 related articles for article (PubMed ID: 29152418)
1. Generation and characterization of cross neutralizing human monoclonal antibody against 4 serotypes of dengue virus without enhancing activity.
Injampa S; Muenngern N; Pipattanaboon C; Benjathummarak S; Boonha K; Hananantachai H; Wongwit W; Ramasoota P; Pitaksajjakul P
PeerJ; 2017; 5():e4021. PubMed ID: 29152418
[TBL] [Abstract][Full Text] [Related]
2. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
[TBL] [Abstract][Full Text] [Related]
3. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
[TBL] [Abstract][Full Text] [Related]
4. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
5. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
6. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
7. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
Uno N; Ross TM
J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
[TBL] [Abstract][Full Text] [Related]
9.
Shukla R; Rajpoot RK; Arora U; Poddar A; Swaminathan S; Khanna N
Front Microbiol; 2017; 8():2644. PubMed ID: 29367852
[TBL] [Abstract][Full Text] [Related]
10. Antibody germline characterization of cross-neutralizing human IgGs against 4 serotypes of dengue virus.
Pitaksajjakul P; Benjathummarak S; Pipattanaboon C; Wongwit W; Okabayashi T; Kuhara M; Misaki R; Fujiyama K; Ramasoota P
Biochem Biophys Res Commun; 2014 Apr; 446(2):475-80. PubMed ID: 24637211
[TBL] [Abstract][Full Text] [Related]
11. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
[TBL] [Abstract][Full Text] [Related]
12. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
13. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
14. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.
de Alwis R; Williams KL; Schmid MA; Lai CY; Patel B; Smith SA; Crowe JE; Wang WK; Harris E; de Silva AM
PLoS Pathog; 2014 Oct; 10(10):e1004386. PubMed ID: 25275316
[TBL] [Abstract][Full Text] [Related]
15. Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.
Wang Y; Si L; Luo Y; Guo X; Zhou J; Fang D; Yan H; Zeng G; Jiang L
Appl Microbiol Biotechnol; 2015 Nov; 99(22):9685-98. PubMed ID: 26219500
[TBL] [Abstract][Full Text] [Related]
16. The human antibody response to dengue virus infection.
Wahala WM; Silva AM
Viruses; 2011 Dec; 3(12):2374-95. PubMed ID: 22355444
[TBL] [Abstract][Full Text] [Related]
17. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
[TBL] [Abstract][Full Text] [Related]
18. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.
Smith SA; Nivarthi UK; de Alwis R; Kose N; Sapparapu G; Bombardi R; Kahle KM; Pfaff JM; Lieberman S; Doranz BJ; de Silva AM; Crowe JE
J Virol; 2016 Jan; 90(2):780-9. PubMed ID: 26512092
[TBL] [Abstract][Full Text] [Related]
19. Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.
Fink AL; Williams KL; Harris E; Alvine TD; Henderson T; Schiltz J; Nilles ML; Bradley DS
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005721. PubMed ID: 28686617
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention.
Goncalvez AP; Engle RE; St Claire M; Purcell RH; Lai CJ
Proc Natl Acad Sci U S A; 2007 May; 104(22):9422-7. PubMed ID: 17517625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
